These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23731911)

  • 1. The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients.
    Brusa L; Pavino V; Massimetti MC; Bove R; Iani C; Stanzione P
    Funct Neurol; 2013; 28(1):13-7. PubMed ID: 23731911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pergolide effect on cognitive functions in early-mild Parkinson's disease.
    Brusa L; Tiraboschi P; Koch G; Peppe A; Pierantozzi M; Ruggieri S; Stanzione P
    J Neural Transm (Vienna); 2005 Feb; 112(2):231-7. PubMed ID: 15365788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.
    Pérez-Pérez J; Pagonabarraga J; Martínez-Horta S; Fernández-Bobadilla R; Sierra S; Pascual-Sedano B; Gironell A; Kulisevsky J
    Drugs Aging; 2015 May; 32(5):401-7. PubMed ID: 25941103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pergolide in the treatment of patients with early and advanced Parkinson's disease.
    Bonuccelli U; Colzi A; Del Dotto P
    Clin Neuropharmacol; 2002; 25(1):1-10. PubMed ID: 11852289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Parkinson's disease should begin with a dopamine agonist.
    Montastruc JL; Rascol O; Senard JM
    Mov Disord; 1999 Sep; 14(5):725-30. PubMed ID: 10495032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.
    Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Yamamoto M; Nakayama T
    PLoS One; 2014; 9(6):e99021. PubMed ID: 24906013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
    Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
    J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
    Bares M; Rektorová I; Krajcovicová L; Rektor I
    J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
    [No Abstract]   [Full Text] [Related]  

  • 17. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
    Relja M; Klepac N
    J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
    Kvernmo T; Härtter S; Burger E
    Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.